Evidence map›Paper›PMID 37285454›Full record

ArticleJournal of proteome research2023

AzidoTMT Enables Direct Enrichment and Highly Multiplexed Quantitation of Proteome-Wide Functional Residues.

Taylur P Ma, Anita Izrael-Tomasevic, Rana Mroue, Hanna Budayeva, Sushant Malhotra, Ryan Raisner, Marie Evangelista, Christopher M Rose, Donald S Kirkpatrick, Kebing Yu

Abstract read
In one paragraph

Article in Journal of proteome research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Taylur P MaDepartment of Microchemistry, Proteomics and Lipidomics, Genentech, 1 DNA Way, South San Francisco, California 94080, United States.ORCID 0009-0005-7546-8366
Anita Izrael-TomasevicDrenBio, Inc., 384 Foster City Boulevard, Foster City, California 94404, United States.
Rana MroueDepartment of Discovery Oncology, Genentech, 1 DNA Way, South San Francisco, California 94080, United States.
Hanna BudayevaDepartment of Microchemistry, Proteomics and Lipidomics, Genentech, 1 DNA Way, South San Francisco, California 94080, United States.
Sushant MalhotraProRavel, Inc., Brisbane, California 94005, United States.
Ryan RaisnerDepartment of Discovery Oncology, Genentech, 1 DNA Way, South San Francisco, California 94080, United States.
Marie EvangelistaDepartment of Discovery Oncology, Genentech, 1 DNA Way, South San Francisco, California 94080, United States.
Christopher M RoseDepartment of Microchemistry, Proteomics and Lipidomics, Genentech, 1 DNA Way, South San Francisco, California 94080, United States.ORCID 0000-0002-7502-3368
Donald S KirkpatrickInterline Therapeutics, Inc., South San Francisco, California 94080, United States.
Kebing YuFuhong Biopharma, Inc., Shanghai 201206, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent advances in targeted covalent inhibitors have aroused significant interest for their potential in drug development for difficult therapeutic targets. Proteome-wide profiling of functional residues is an integral step of covalent drug discovery aimed at defining actionable sites and evaluating compound selectivity in cells. A classical workflow for this purpose is called IsoTOP-ABPP, which employs an activity-based probe and two isotopically labeled azide-TEV-biotin tags to mark, enrich, and quantify proteome from two samples. Here we report a novel isobaric 11plex-AzidoTMT reagent and a new workflow, named AT-MAPP, that significantly expands multiplexing power as compared to the original isoTOP-ABPP. We demonstrate its application in identifying cysteine on- and off-targets using a KRAS G12C covalent inhibitor ARS-1620. However, changes in some of these hits can be explained by modulation at the protein and post-translational levels. Thus, it would be crucial to interrogate site-level bona fide changes in concurrence to proteome-level changes for corroboration. In addition, we perform a multiplexed covalent fragment screening using four acrylamide-based compounds as a proof-of-concept. This study identifies a diverse set of liganded cysteine residues in a compound-dependent manner with an average hit rate of 0.07% in intact cell. Lastly, we screened 20 sulfonyl fluoride-based compounds to demonstrate that the AT-MAPP assay is flexible for noncysteine functional residues such as tyrosine and lysine. Overall, we envision that 11plex-AzidoTMT will be a useful addition to the current toolbox for activity-based protein profiling and covalent drug development.

Indexed as

CysteineProteomeDrug DiscoveryProtein Processing, Post-TranslationalProteomicsCysteineProteomechemoproteomicscysteine profilingisobaric labelingmass spectrometryOrbitrapquantitative proteomicsTMT

Identifiers

PMID37285454
PMCPMC10337260

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.